

*Ruetzler K, Szarpak Ł, Ładny JR, et al. D-dimer levels predict COVID-19 severity and mortality. Radiol Pol. 2021; 79: 217-218. doi:10.33963/KP.15830*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.


## **D-dimer levels predict COVID-19 severity and mortality**

### **SUPPLEMENTARY DIGITAL CONTENT**

#### **CONTENT:**

<b>D-DIMER LEVELS IN SEVERE VS. NON-SEVERE COMPARISON .....</b>	<b>2</b>
<b>SUPPLEMENTARY FIGURE 1. FOREST PLOT OF D-DIMER LEVELS IN SEVERE VS. NON-SEVERE GROUP.....</b>	<b>2</b>
<b>SUPPLEMENTARY TABLE 1. STUDIES INCLUDED IN COMPARISON SEVERE VS. NON-SEVERE.....</b>	<b>2</b>
<b>D-DIMER LEVELS IN ICU VS. NON-ICU COMPARISON.....</b>	<b>5</b>
<b>SUPPLEMENTARY FIGURE 2. FOREST PLOT OF D-DIMER LEVELS IN ICU VS. NON-ICU GROUP. ....</b>	<b>5</b>
<b>SUPPLEMENTARY TABLE 2. STUDIES INCLUDED IN ICU VS. NON-ICU COMPARISON .....</b>	<b>5</b>
<b>D-DIMER LEVELS IN DEATH VS. SURVIVAL GROUPS.....</b>	<b>7</b>
<b>SUPPLEMENTARY FIGURE 3. FOREST PLOT OF D-DIMER LEVELS IN DEATH VS. SURVIVAL GROUP.....</b>	<b>7</b>
<b>SUPPLEMENTARY TABLE 3. STUDIES INCLUDED IN DEATH VS. SURVIVAL COMPARISON .....</b>	<b>7</b>

## D-dimer levels in severe vs. non-severe comparison



**Supplementary Figure 1.** Forest plot of D-dimer levels in severe vs. non-severe group. The center of each square represents the weighted mean difference for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results.

**Supplementary Table 1.** Studies included in comparison severe vs. non-severe

Study	Country	Study design	Severe group			Non-severe group		
			No.	Age	Sex, male	No.	Age	Sex, male
Chen G. et al. 2020 <sup>(1)</sup>	China	Retrospective study	11	61.1 ± 2.8	10 (90.9%)	10	50.7 ± 3.8	7 (70.0%)
Chen LD. Et al. 2020 <sup>(2)</sup>	China	Retrospective study	25	60.7 ± 15.2	15 (60.0%)	69	51.4 ± 15.8	34 (49.3%)
Chen R. et al. 2020 <sup>(3)</sup>	China	Retrospective study	203	61 ± 13.7	131 (64.5%)	345	67.3 ± 12.1	182 (52.8%)
Cugno M. et al. 2020 <sup>(4)</sup>	Italy	Retrospective study	14	NS	NS	17	NS	NS
Gao Y. et al. 2020 <sup>(5)</sup>	China	Retrospective study	15	45.2 ± 7.7	9 (60.0%)	28	42.9 ± 14.0	17 (60.7%)
Guirao JJ. et al. 2020 <sup>(6)</sup>	Spain	Cohort study	6	64.5 ± 2.3	5 (83.3%)	44	63.4 ± 4.5	36 (81.8%)
Gunder R. et al. 2020 <sup>(7)</sup>	Turkey	Retrospective study	50	62.2 ± 11.9	33 (66.0%)	172	47.7 ± 16.1	99 (57.6%)
Han Y. et al. 2020 <sup>(8)</sup>	China	Retrospective study	48	66.5 ± 5.8	31 (64.4%)	59	58.5 ± 7.5	29 (49.2%)
Li Q. et al. 2020 <sup>(9)</sup>	China	Retrospective study	26	67.3 ± 3.8	20 (76.9%)	296	49.3 ± 4.5	147 (49.8%)
Liu J. et al. 2020 (a) <sup>(10)</sup>	China	Retrospective study	13	59.7 ± 10.1	7 (53.8%)	27	43.2 ± 12.3	8 (29.6%)
Liu J. et al. 2020 (b) <sup>(11)</sup>	China	Retrospective study	152	70.1 ± 4.7	88 (57.9%)	62	62.2 ± 6.1	31 (50.0%)
Lu Y. et al. 2020 <sup>(12)</sup>	China	Retrospective study	9	68.8 ± 4.3	8 (88.9%)	44	53.3 ± 6.9	26 (59.1%)

Popov GT. et al. 2020 <sup>(13)</sup>	Bulgaria	Retrospective study	43	63.0 ± 12.8	33 (76.8%)	95	48.3 ± 15.7	54 (56.9%)
Shah A. et al. 2020 <sup>(14)</sup>	UK	Retrospective study	10	60.5 ± 6.4	5 (50.0%)	20	57.5 ± 3.5	12 (60.0%)
Shang W. et al. 2020 <sup>(15)</sup>	China	Retrospective study	139	63.8 ± 3.2	57 (41.0%)	304	57.5 ± 3.3	166 (54.6%)
Wan S. et al. 2020 <sup>(16)</sup>	China	Case series	40	59.3 ± 6.1	21 (52.5%)	95	42.5 ± 2.7	52 (54.7%)
Wang F. et al. 2020 <sup>(17)</sup>	China	Retrospective study	35	61.3 ± 12.2	NS	30	52.2 ± 12.4	NS
Xie L. et al. 2020 <sup>(18)</sup>	China	Retrospective study	38	59.8 ± 7.5	14 (36.8%)	24	68.6 ± 5.6	13 (54.2%)
Xiong S. et al. 2020 <sup>(19)</sup>	China	Retrospective study	55	64.3 ± 6.6	38 (69.1%)	61	66 ± 6.9	42 (68.9%)
Xu X. et al. 2020 <sup>(20)</sup>	China	Retrospective study	41	63.2 ± 14.5	15 (31.9%)	47	52.5 ± 14.6	21 (44.7%)
Xue G. et al. 2020 <sup>(21)</sup>	China	Retrospective study	58	62.7 ± 6.7	34 (58.6%)	56	60.5 ± 4.8	30 (53.6%)
Yuan X. et al. 2020 <sup>(22)</sup>	China	Retrospective study	56	57.8 ± 6.6	26 (46.4%)	61	63.3 ± 4.3	30 (49.2%)
Zhao K. et al. 2020 <sup>(23)</sup>	China	Retrospective study	31	59.3 ± 7.3	23 (74.2%)	19	49.8 ± 8.4	7 (36.8%)


Legend: NS = Not specified;

#### References:

- Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020; 130(5):2620-2629. doi: 10.1172/JCI137244.
- Chen LD, Zhang ZY, Wei XJ, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. *Respir Res.* 2020; 21(1):201. doi: 10.1186/s12931-020-01465-2.
- Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. *J Allergy Clin Immunol.* 2020; 146(1):89-100. doi: 10.1016/j.jaci.2020.05.003.
- Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: A novel therapeutic target. *J Allergy Clin Immunol.* 2020 Jul;146(1):215-217. doi: 10.1016/j.jaci.2020.05.006.
- Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol.* 2020 Jul;92(7):791-796. doi: 10.1002/jmv.25770.
- Guirao JJ, Cabrera CM, Jiménez N, et al. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol.* 2020 Oct 14;128:64-68. doi: 10.1016/j.molimm.2020.10.006.
- Güner R, Hasanoğlu I, Kayaaslan B, et al. COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey. *Turk J Med Sci.* 2020 Jul 19. doi: 10.3906/sag-2006-164.
- Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. *Aging (Albany NY).* 2020 Jun 24;12(12):11245-11258. doi: 10.18632/aging.103372.
- Li Q, Zhang J, Ling Y, et al. A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. *Infection.* 2020 Aug;48(4):577-584. doi: 10.1007/s15010-020-01446-z.
- Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.* 2020; 55:102763. doi: 10.1016/j.ebiom.2020.102763.
- Liu J, Liu Z, Jiang W, et al. Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalised patients from Wuhan, China. *Clin Respir J.* 2020 Oct 22. doi: 10.1111/crj.13296.
- Lu Y, Sun K, Guo S, et al. Early Warning Indicators of Severe COVID-19: A Single-Center Study of Cases From Shanghai, China. *Front Med (Lausanne).* 2020 Jul 17;7:432. doi: 10.3389/fmed.2020.00432.
- Popov GT, Baymakova M, Vaseva V, Kundurzhiev T, Mutafchiyski V. Clinical Characteristics of Hospitalized Patients with COVID-19 in Sofia, Bulgaria. *Vector Borne Zoonotic Dis.* 2020 Oct 14. doi: 10.1089/vbz.2020.2679.
- Shah A, Frost JN, Aaron L, et al. Systemic hypoferrremia and severity of hypoxemic respiratory failure in COVID-19. *Crit Care.* 2020; 24(1):320. doi: 10.1186/s13054-020-03051-w.
- Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. *J Med Virol.* 2020 May 21;10.1002/jmv.26031. doi: 10.1002/jmv.26031.
- Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol.* 2020 Jul;92(7):797-806. doi: 10.1002/jmv.25783.

17. Wang F, Hou H, Luo Y, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. *JCI Insight*. 2020 May 21;5(10):e137799. doi: 10.1172/jci.insight.137799.
18. Zie Y, You Q, Wu C, et al. Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19). *Circ J*. 2020 Jul 22;84(8):1277-1283. doi: 10.1253/circj.CJ-20-0348.
19. Xiong S, Liu L, Lin F, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. *BMC Infect Dis*. 2020 Oct 22;20(1):787. doi: 10.1186/s12879-020-05452-2.
20. Xu Y, Li Y, Zeng Q, et al. Clinical Characteristics of SARS-CoV-2 Pneumonia Compared to Controls in Chinese Han Population. *medRxiv* 2020. doi: 10.1101/2020.03.08.20031658v1.
21. Xue G, Gan X, Wu Z, et al. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19. *Int Immunopharmacol*. 2020 Oct 3;89(Pt A):107065. doi: 10.1016/j.intimp.2020.107065.
22. Yuan X, Huang W, Ye B, et al. Changes of hematological and immunological parameters in COVID-19 patients. *Int J Hematol*. 2020 Oct;112(4):553-559. doi: 10.1007/s12185-020-02930-w.
23. Zhao K, Huang J, Dai D, et al. Serum Iron Level as a Potential Predictor of Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study. *Open Forum Infect Dis*. 2020 Jun 21;7(7):ofaa250. doi: 10.1093/ofid/ofaa250.

## D-dimer levels in ICU vs. non-ICU comparison



**Supplementary Figure 2.** Forest plot of D-dimer levels in ICU vs. non-ICU group. The center of each square represents the weighted mean difference for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results.

**Supplementary Table 2.** Studies included in ICU vs. non-ICU comparison


Study	Country	Study design	ICU group			Non-ICU group		
			No.	Age	Sex, male	No.	Age	Sex, male
Almazeedi S. et al. 2020 <sup>(1)</sup>	Kuwait	Retrospective study	42	54.8 ± 11	32 (76.2%)	1054	37.1 ± 16	856 (81.2%)
Aloisio E. et al. 2020 <sup>(2)</sup>	Italy	Retrospective study	47	63.8 ± 3.7	41 (87.2%)	380	67 ± 4.5	252 (66.3%)
Bastug A. et al. 2020 <sup>(3)</sup>	Turkey	Retrospective study	46	65.5 ± 18.5	26 (56.5%)	145	46.8 ± 10.8	81 (55.9%)
Carlino MV. et al. 2020 <sup>(4)</sup>	Italy	Observational study	10	73 ± 7.4	8 (80.0%)	18	47 ± 12.6	10 (55.6%)
El Aidaoui K. et al. 2020 <sup>(5)</sup>	Marroco	Retrospective observational study	45	64.8 ± 4.9	35 (77.9%)	89	42.3 ± 7.8	38 (42.7%)
Guirao JJ. et al. 2020 <sup>(6)</sup>	Spain	Cohort study	8	62.1 ± 2.8	7 (87.5%)	42	63.8 ± 1.8	34 (80.9%)
Huang C. et al. 2020 <sup>(7)</sup>	China	Retrospective study	21	61.4 ± 16.4	12 (57.1%)	43	41.2 ± 15.7	25 (58.1%)
Liu SP et al. 2020 <sup>(8)</sup>	China	Retrospective study	41	63 ± 15	28 (71.8%)	214	61 ± 11.3	108 (50.9%)
Maeda T. et al. 2020 <sup>(9)</sup>	USA	Retrospective study	57	67 ± 5.2	31 (54.4%)	167	64.5 ± 4.3	96 (57.5%)
Sun Y. et al. 2020 <sup>(10)</sup>	China	Retrospective study	19	59.4 ± 13.7	NS	44	42.3 ± 19.7	NS
Wang D. et al. 2020 <sup>(11)</sup>	China	Retrospective case series	36	66.8 ± 6.1	22 (61.1%)	102	50.3 ± 4.2	53 (52.0%)
Zhou J et al. 2020 <sup>(12)</sup>	China	Retrospective study	45	56.5 ± 5.8	27 (60.0%)	156	41 ± 3.7	75 (48.1%)

Legend: NS = Not specified;

## References:

1. Almazeedi S, Al-Youha S, Jamal MH, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. *EClinicalMedicine*. 2020 Jul 4;24:100448. doi: 10.1016/j.eclinm.2020.100448.
2. Aloisio A, Chibireva M, Serafini L, et al. A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. *Arch Pathol Lab Med*. 2020 Jul 10. doi: 10.5858/arpa.2020-0389-SA.
3. Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. *Int Immunopharmacol*. 2020 Nov;88:106950. doi: 10.1016/j.intimp.2020.106950.
4. Carlino MV, Valenti N, Cesaro F, et al. Predictors of Intensive Care Unit admission in patients with coronavirus disease 2019 (COVID-19). *Monaldi Arch Chest Dis*. 2020 Jul 15;90(3). doi: 10.4081/monaldi.2020.1410.
5. El Aidaoui K, Haoudar A, Khalis M, et al. Predictors of Severity in Covid-19 Patients in Casablanca, Morocco. *Cureus*. 2020; 12(9):e10716. doi: 10.7759/cureus.10716.
6. Guirao JJ, Cabrera CM, Jiménez N, et al. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol*. 2020 Oct 14;128:64-68. doi: 10.1016/j.molimm.2020.10.006.
7. Huang H, Song B, Xu Z, et al. Predictors of coronavirus disease 2019 severity: A retrospective study of 64 cases. *Jpn J Infect Dis*. 2020 Aug 1. doi: 10.7883/yoken.JJID.2020.298.
8. Liu SP, Zhang Q, Wang W, et al. Hyperglycemia is a strong predictor of poor prognosis in COVID-19. *Diabetes Res Clin Pract*. 2020; 167:108338. doi: 10.1016/j.diabres.2020.108338.
9. Maeda T, Obata R, Do DR, Kuno T. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. *J Med Virol*. 2020 Jul 28. doi: 10.1002/jmv.26365.
10. Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *J Autoimmun*. 2020 Aug;112:102473. doi: 10.1016/j.jaut.2020.102473.
11. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
12. Zhou J, Sun J, Cao Z, et al. Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China. *Medicine (Baltimore)*. 2020 Aug 21;99(34):e21824. doi: 10.1097/MD.00000000000021824.

## D-dimer levels in death vs. survival groups



**Supplementary Figure 3.** Forest plot of D-dimer levels in death vs. survival group. The center of each square represents the weighted mean difference for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results.

**Supplementary Table 3.** Studies included in death vs. survival comparison

Study	Country	Study design	Death group			Survival group		
			No.	Age	Sex, male	No.	Age	Sex, male
Almazeedi S. et al. 2020 <sup>(1)</sup>	Kuwait	Retrospective study	19	55.0 ± 10.1	16 (84.2%)	1077	38.7 ± 15.1	872 (81.0%)
Aloisio E. et al. 2020 <sup>(2)</sup>	Italy	Retrospective study	89	73.3 ± 2.2	70 (78.7%)	338	58.3 ± 3.5	223 (65.9%)
Asghar MS. et al. 2020 <sup>(3)</sup>	Pakistan	Retrospective observational multicenter study	101	61.0 ± 11.6	66 (65.3%)	263	49.3 ± 16.1	66 (25.1%)
Bonetti G. et al. 2020 <sup>(4)</sup>	Italy	Cohort study	70	76.1 ± 5.7	45 (64.3%)	74	62.5 ± 3.3	51 (68.9%)
Chen R. et al. 2020 <sup>(5)</sup>	China	Retrospective study	103	66.9 ± 12.1	69 (67.0%)	445	53.5 ± 13.9	244 (54.8%)
Covino M. et al. 2020 <sup>(6)</sup>	Italy	Single-center retrospective observational study	23	84.8 ± 0.8	12 (52.2%)	46	84.5 ± 2.3	25 (54.3%)
Gao S. et al. 2020 <sup>(7)</sup>	China	Retrospective study	35	75 ± 3.5	22 (62.9%)	175	70.3 ± 1.2	79 (45.1%)
Garcia PDW. et al. 2020 <sup>(8)</sup>	Multi-country	Prospective observational cohort study	97	70.5 ± 2.7	69 (71.1%)	301	62 ± 2.7	231 (76.7%)
Guirao JJ. et al. 2020 <sup>(9)</sup>	Spain	Cohort study	14	69.0 ± 3.1	11 (78.6%)	36	61.4 ± 1.7	30 (83.3%)
Kaske S. et al. 2020 <sup>(10)</sup>	Turkey	Retrospective study	6	74 ± 5.2	6 (100%)	37	60.8 ± 19.3	18 (56.8%)
Laguna-Goya R. et al. 2020 <sup>(11)</sup>	Spain	Prospective cohort study	36	64.8 ± 4.3	25 (69.4%)	465	51.5 ± 2.3	292 (62.9%)

Li K. et al. 2020 <sup>(12)</sup>	China	Retrospective study	15	68.3 ± 5.5	11 (73.3%)	87	55 ± 3.7	48 (55.2%)
Li Q. et al. 2020 <sup>(13)</sup>	China	Retrospective study	26	67.3 ± 3.8	20 (76.9%)	296	49.3 ± 4.5	147 (49.8%)
Lohse A. et al. 2020 <sup>(14)</sup>	France	Retrospective study	10	80 ± 10.1	NS	24	73.1 ± 11.1	NS
Ronderos Botero DM. et al. 2020 <sup>(15)</sup>	USA	Retrospective study	25	62.4 ± 12.7	20 (80.0%)	132	50.6 ± 17.1	89 (67.4%)
Wang J. et al. 2020 <sup>(16)</sup>	China	Retrospective study	NS	NS	NS	NS	NS	NS
Zhou F. et al. 2020 <sup>(17)</sup>	China	Retrospective multicenter cohort study	54	69.3 ± 3.8	38 (70.4%)	137	51.8 ± 2.2	81 (59.1%)

Legend: NS = Not specified;

## References:

1. Almazeedi S, Al-Youha S, Jamal MH, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. *EClinicalMedicine*. 2020 Jul 4;24:100448. doi: 10.1016/j.eclinm.2020.100448.
2. Aloisio A, Chibireva M, Serafini L, et al. A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. *Arch Pathol Lab Med*. 2020 Jul 10. doi: 10.5858/arpa.2020-0389-SA.
3. Asghar MS, Kazmi SJH, Khan NA, et al. Poor Prognostic Biochemical Markers Predicting Fatalities Caused by COVID-19: A Retrospective Observational Study From a Developing Country. *Cureus*. 2020 Aug 5;12(8):e9575. doi: 10.7759/cureus.9575.
4. Bonetti G, Manelli F, Patroni A, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. *Clin Chem Lab Med*. 2020 Jun 25;58(7):1100-1105. doi: 10.1515/cclm-2020-0459.
5. Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. *J Allergy Clin Immunol*. 2020 Jul;146(1):89-100. doi: 10.1016/j.jaci.2020.05.003.
6. Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. *Geriatr Gerontol Int*. 2020 Jul;20(7):704-708. doi: 10.1111/ggi.13960.
7. Gao S, Jiang F, Jin W, ET AL.. Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China. *Aging (Albany NY)*. 2020 Jul 11;12(13):12504-12516. doi: 10.18632/aging.103631.
8. Garcia PDW, Fumeaux T, Guerci P, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. *EClinicalMedicine*. 2020 Aug;25:100449. doi: 10.1016/j.eclinm.2020.100449.
9. Guirao JJ, Cabrera CM, Jiménez N, et al. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol*. 2020 Oct 14;128:64-68. doi: 10.1016/j.molimm.2020.10.006.
10. Keske Ş, Tekin S, Sait B, et al. Appropriate use of tocilizumab in COVID-19 infection. *Int J Infect Dis*. 2020 Oct;99:338-343. doi: 10.1016/j.ijid.2020.07.036.
11. Laguna-Goya R, Utrero-Rico A, Talayero P, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. *J Allergy Clin Immunol*. 2020; 146(4):799-807.e9. doi: 10.1016/j.jaci.2020.07.009.
12. Li K, Chen D, Chen S, et al. Predictors of fatality including radiographic findings in adults with COVID-19. *Respir Res*. 2020 Jun 11;21(1):146. doi: 10.1186/s12931-020-01411-2.
13. Li Q, Zhang J, Ling Y, et al. A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. *Infection*. 2020; 48(4):577-584. doi: 10.1007/s15010-020-01446-z.
14. Lohse A, Klopfenstein T, Balblanc JC, et al. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). *Microbes Infect*. 2020; 22(9):500-503. doi: 10.1016/j.micinf.2020.06.005.
15. Ronderos Botero DM, Omar AMS, Sun HK, et al. COVID-19 in the Healthy Patient Population: Demographic and Clinical Phenotypic Characterization and Predictors of In-Hospital Outcomes. *Arterioscler Thromb Vasc Biol*. 2020; 40(11):2764-2775. doi: 10.1161/ATVBAHA.120.314845.
16. Wang J, Yu H, Hua Q, et al. A descriptive study of random forest algorithm for predicting COVID-19 patients outcome. *PeerJ*. 2020 Sep 9;8:e9945. doi: 10.7717/peerj.9945. eCollection 2020.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020; 395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.